

## Engineering $\alpha$ -Helical Antimicrobial Peptides as Nanoscale Tools to Combat Multidrug-Resistant Bacteria

**Erika Saccullo**<sup>1,2</sup>, Vincenzo Patamia<sup>1</sup>, Michele Larocca<sup>3</sup>, Virginia Fuochi<sup>2</sup>, Salvatore Furnari<sup>2</sup>, Pio Maria Furneri<sup>2</sup>, Agostino Cilibrizzi<sup>4,5</sup>, Giuseppe Floresta<sup>1</sup>

<sup>1</sup> Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy

<sup>2</sup> Department of Biomedical and Biotechnological Sciences (Biometec), University of Catania, Via Santa Sofia 97, 95123 Catania, Italy

<sup>3</sup> Department of Chemistry and Biology "Adolfo Zambelli", University of Salerno, Via Giovanni Paolo II 132, 84084, Fisciano (Salerno), Italy


<sup>4</sup> Institute of Pharmaceutical Science, King's College London, Stamford Street, London SE1 9NH, UK

<sup>5</sup> Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK

[erika.saccullo@phd.unict.it](mailto:erika.saccullo@phd.unict.it)


### INTRODUCTION & AIM

Multidrug-resistant bacteria represent a critical global health threat.  $\alpha$ -Helical antimicrobial peptides (AMPs) act by disrupting bacterial membranes and are less prone to resistance. In this study, we designed new  $\alpha$ -helical AMPs using the MMFs method and enhanced their activity with metal-chelating agents such as allomaltol.



### METHODS

Peptides were designed via MMF-based dihedral angle calculations to predict stable  $\alpha$ -helical conformations. They were synthesized using Fmoc solid-phase peptide synthesis and characterized by FT-IR, HPLC, and ESI+ MS. Antibacterial activity was evaluated by broth microdilution assays against *S. aureus*, *E. coli*, and *K. pneumoniae*.




Schematic synthesis of K1-4-5-A

### RESULTS & DISCUSSION

**HT2**, the reference peptide, exhibited strong activity against *Staphylococcus aureus* (MIC 18.75  $\mu$ M), moderate effects against *Escherichia coli* (75  $\mu$ M), and limited activity against *Klebsiella pneumoniae* (150  $\mu$ M). Structural analogues designed with MMFs showed different outcomes: **K1** (Arg1→Lys) lost activity completely, confirming the essential role of Arg1; **K1-4-5** (Arg1/4/5→Lys) retained partial antimicrobial effects. The co-administration of peptides with allomaltol significantly enhanced activity, lowering MIC values to 37.5  $\mu$ M for *S. aureus* and *E. coli*, suggesting a clear synergistic effect between membrane disruption and metal ion chelation. Most notably, the covalently modified derivative **K1-4-5-A**, carrying a maltol-like chelating group, restored potent and selective activity against *S. aureus* (MIC 18.75  $\mu$ M), comparable to HT2. These findings support the dual-action strategy as a way to boost potency and reduce resistance risk.

Compounds	<i>S. aureus</i>	<i>K. pneumoniae</i>	<i>E. coli</i>
<b>HT2</b>	18.75 $\mu$ M	150 $\mu$ M	75 $\mu$ M
<b>K1</b>	300 $\mu$ M	300 $\mu$ M	300 $\mu$ M
<b>K1-4-5</b>	300 $\mu$ M	150 $\mu$ M	75 $\mu$ M
Allomaltol	300 $\mu$ M	300 $\mu$ M	300 $\mu$ M
<b>K1-allomaltol 1:1</b>	75 $\mu$ M	300 $\mu$ M	150 $\mu$ M
<b>K1-allomaltol 1:2</b>	75 $\mu$ M	300 $\mu$ M	150 $\mu$ M
<b>K1-4-5</b>	300 $\mu$ M	150 $\mu$ M	75 $\mu$ M
<b>K1-4-5-allomaltol 1:1</b>	37.5 $\mu$ M	75 $\mu$ M	37.5 $\mu$ M
<b>K1-4-5-allomaltol 1:2</b>	37.5 $\mu$ M	75 $\mu$ M	37.5 $\mu$ M
<b>K1-4-5-A</b>	18.75 $\mu$ M	300 $\mu$ M	75 $\mu$ M

Minimum inhibitory concentrations (MICs, expressed in  $\mu$ M) of the tested compounds and their combinations against three bacterial strains.



### CONCLUSION

This work shows that MMF-guided peptide design is a powerful strategy for creating stable and effective  $\alpha$ -helical AMPs. The dual mechanism of action (membrane disruption combined with metal chelation) enhances antimicrobial activity and selectivity against resistant bacteria. These results highlight a promising nanoscale approach for next-generation antimicrobial therapeutics, paving the way for further *in vivo* studies and clinical translation.

### REFERENCES

- Cilibrizzi, A.; Abbate, V.; Chen, Y. L.; Ma, Y.; Zhou, T.; Hider, R. C., Hydroxypyridinone Journey into Metal Chelation. *Chem. Rev.* **2018**, *118* (16), 7657–7701.
- Larocca, M.; Floresta, G.; Verderese, D.; Cilibrizzi, A., 'Main Mechanical Forces-Chemical Interactions' Interplay as a Tool to Elucidate Folding Mechanisms. *Peptide Science* **2024**, *116* (5).
- Larocca, M.; Foglia, F.; Cilibrizzi, A., Dihedral Angle Calculations To Elucidate the Folding of Peptides through Its Main Mechanical Forces. *Biochemistry* **2019**, *58* (8), 1032–1037.
- Larocca, M.; Floresta, G.; Cilibrizzi, A., Principles that rule the calculation of dihedral angles in secondary structures: the cases of an  $\alpha$ -helix and a  $\beta$ -sheet. *J. Mol. Struct.* **2021**, 1229.